Dextera Biosciences

Executive Summary

Dextera Biosciences is a private biotechnology company pioneering a novel class of therapeutics called 'dexabodies'—drugs engineered entirely from D-amino acids. This unique composition renders them resistant to natural degradation enzymes, enabling prolonged activity, deep tissue penetration, and rapid clearance, thereby addressing key limitations of traditional biologics such as poor stability and limited biodistribution. The platform has the potential to improve efficacy and safety across a range of indications, including oncology, inflammatory diseases, and rare disorders. Founded in 2015 and headquartered in San Diego, the company is currently in the clinical stage, having initiated Phase 1 trials for its lead candidate in 2025. The upcoming period is critical for Dextera as it advances its lead dexabody through first-in-human studies. Initial Phase 1 data, expected in late 2026 or early 2027, will provide the first clinical proof-of-concept, assessing safety, tolerability, and pharmacokinetics. Positive results could validate the platform and attract partnership interest from larger pharmaceutical companies seeking next-generation biologics. The company's innovative approach and early-stage momentum position it as a potential disruptor in the biologics space, though clinical execution and funding remain key risks.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 clinical data readout for lead dexabody candidate55% success
• H2 2026Strategic partnership or licensing deal for platform technology40% success
• Q1 2027IND filing for second dexabody program70% success